DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Niaspan treatment improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.

Author(s): Zhang J, Chen J, Li Y, Cui X, Zheng X, Roberts C, Lu M, Elias SB, Chopp M

Affiliation(s): Department of Neurology, Henry Ford Health System, Detroit, MI 48202, USA.

Publication date & source: 2008-11, Neurobiol Dis., 32(2):273-80. Epub 2008 Jul 29.

Publication type: Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

We investigated the treatment of experimental autoimmune encephalomyelitis (EAE) in mice with Niaspan, an agent used to elevate high-density lipoprotein (HDL). EAE mice were treated with Niaspan starting on the immunization or clinical onset day. Neurological functional recovery was significantly increased in the Niaspan treated mice (100 mg/kgbw) compared to the controls. Inflammatory infiltrates were significantly reduced in the Niaspan treatment group compared to the EAE controls. HDL level, intact myelin area, newly formed oligodendrocytes, regenerating axons, gene and protein levels of sonic hedgehog (Shh)/Gli1 were significantly increased in the Niaspan treated mice compared to EAE controls. These data indicate that Niaspan treatment improved functional recovery after EAE, possibly, via reducing inflammatory infiltrates and demyelination areas, and stimulating oligodendrogenesis and axonal regeneration. Niaspan-mediated activation of Shh/Gli1 pathway may promote functional recovery post-EAE.

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017